for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Vertex Pharmaceuticals Incorporated

VRTX.O

Latest Trade

207.15USD

Change

-4.43(-2.09%)

Volume

2,087,453

Today's Range

204.84

 - 

210.54

52 Week Range

192.32

 - 

306.08

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
211.58
Open
209.75
Volume
2,087,453
3M AVG Volume
35.77
Today's High
210.54
Today's Low
204.84
52 Week High
306.08
52 Week Low
192.32
Shares Out (MIL)
260.47
Market Cap (MIL)
55,109.68
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2020 Vertex Pharmaceuticals Inc Earnings Release

Latest Developments

More

Vertex Pharmaceuticals- On September 18, Co Entered Into A Credit Agreement

Moderna And Vertex Establish New Collaboration To Treat Cystic Fibrosis Using Gene Editing

Janssen To Discontinue Pimodivir Influenza Development Program

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

Industry

Biotechnology & Drugs

Contact Info

50 Northern Ave

BOSTON, MA

02210-1862

United States

+1.617.3416393

https://www.vrtx.com/

Executive Leadership

Jeffrey M. Leiden

Executive Chairman of the Board

Reshma Kewalramani

President, Chief Executive Officer, Director

Charles F. Wagner

Chief Financial Officer, Executive Vice President

Michael J. Parini

Executive Vice President, Chief Legal and Administrative Officer

David Altshuler

Executive Vice President - Global Research, Chief Scientific Officer

Key Stats

2.00 mean rating - 25 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

2.2K

2018

3.0K

2019

4.0K

2020(E)

6.0K
EPS (USD)

2017

1.950

2018

4.080

2019

5.330

2020(E)

9.796
Price To Earnings (TTM)
26.74
Price To Sales (TTM)
10.20
Price To Book (MRQ)
7.32
Price To Cash Flow (TTM)
25.21
Total Debt To Equity (MRQ)
6.94
LT Debt To Equity (MRQ)
6.94
Return on Investment (TTM)
29.32
Return on Equity (TTM)
24.13

Latest News

Latest News

BRIEF-Vertex Announces Expansion Of Reimbursement Agreement With NHS England To Include Kaftrio® In Combination With Kalydeco®

* VERTEX ANNOUNCES EXPANSION OF REIMBURSEMENT AGREEMENT WITH NHS ENGLAND TO INCLUDE KAFTRIO® (IVACAFTOR/TEZACAFTOR/ELEXACAFTOR) IN COMBINATION WITH KALYDECO® (IVACAFTOR)

Vertex treatment for rare genetic disorder wins EU watchdog backing

A panel of the European health regulator on Friday recommended approving Vertex Pharmaceuticals' triple-combination treatment for cystic fibrosis (CF), a rare, deadly genetic disorder that causes the build-up of thick mucus in some body parts. The European Medicines Agency...

EU drug regulator endorses Vertex's triple-combo cystic fibrosis treatment

Europe's health regulator said on Friday its panel has recommended approval of Vertex Pharmaceuticals' triple-combination treatment for cystic fibrosis (CF), a deadly disease that causes build-up of thick mucus in some parts of the body.

BRIEF-Vertex Appoints Diana Mckenzie To Its Board Of Directors

* ADDITION OF MCKENZIE BRINGS VERTEX'S BOARD OF DIRECTORS TO 10 MEMBERS, 8 OF WHOM ARE INDEPENDENT Source text for Eikon: Further company coverage:

BRIEF-Crispr Therapeutics And Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (Rmat) Designation Granted To Ctx001™ For The Treatment Of Severe Hemoglobinopathies

* CRISPR THERAPEUTICS AND VERTEX PHARMACEUTICALS ANNOUNCE FDA REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION GRANTED TO CTX001™ FOR THE TREATMENT OF SEVERE HEMOGLOBINOPATHIES Source text for Eikon: Further company coverage:

BRIEF-Vertex Receives European CHMP Positive Opinion For Kalydeco (Ivacaftor) For Children And Adolescents With Cystic Fibrosis

* RECEIVES EUROPEAN CHMP POSITIVE OPINION FOR KALYDECO (IVACAFTOR) FOR CHILDREN AND ADOLESCENTS WITH CYSTIC FIBROSIS BETWEEN THE AGES 6 MONTHS AND 18 YEARS WITH THE R117H MUTATION IN THE CFTR GENE

BRIEF-Vertex Reports First-Quarter 2020 Financial Results

* QTRLY PRODUCT REVENUES, NET $1,515 MILLION VERSUS $857 MILLION

BRIEF-Vertex Pharma Says CEO Jeffrey Leiden's FY 2019 Total Compensation Was $18.8 Mln Vs $18.8 Mln In FY 2018

* VERTEX PHARMACEUTICALS INC SAYS CEO JEFFREY LEIDEN'S FY 2019 TOTAL COMPENSATION WAS $18.8 MILLION VERSUS $18.8 MILLION IN FY 2018 - SEC FILING

BRIEF-Vertex Pharmaceuticals And Affinia Therapeutics Establish Multi-Year Collaboration

* VERTEX PHARMACEUTICALS AND AFFINIA THERAPEUTICS ESTABLISH MULTI-YEAR COLLABORATION TO DISCOVER AND DEVELOP NOVEL AAV CAPSIDS FOR GENETIC THERAPIES

Drugmaker Vertex to delay new clinical studies due to coronavirus

U.S. drugmaker Vertex Pharmaceuticals Inc said on Friday it would delay starting some clinical trials and temporarily pause enrolment in some studies, as it looks to free up hospitals to deal with the coronavirus outbreak.

BRIEF-Vertex Confirms Supply Chain Continuity And Business Outlook For Its Cystic Fibrosis Medicines And Provides Initial Update On Development Programs

* VERTEX CONFIRMS SUPPLY CHAIN CONTINUITY AND BUSINESS OUTLOOK FOR ITS CYSTIC FIBROSIS MEDICINES AND PROVIDES INITIAL UPDATE ON DEVELOPMENT PROGRAMS

BRIEF-Cardiex Ltd Announces Additional Contract With Bayer AG

* CARDIEX LTD ANNOUNCES ADDITIONAL CONTRACT WITH PHARMACEUTICAL GIANT, BAYER AG

BRIEF-Vertex Confirms Supply Chain Continuity And 2020 Business Outlook

* VERTEX CONFIRMS SUPPLY CHAIN CONTINUITY AND 2020 BUSINESS OUTLOOK

BRIEF-Vertex Cancels March 3 Presentation At The Cowen Health Care Conference

* VERTEX ANNOUNCES CANCELLATION OF ITS MARCH 3 PRESENTATION AT THE COWEN HEALTH CARE CONFERENCE

BRIEF-CRISPR Therapeutics And Vertex Announce Data From Two Patients Treated With Gene-Editing Therapy CTX001

* CRISPR THERAPEUTICS AND VERTEX ANNOUNCE POSITIVE SAFETY AND EFFICACY DATA FROM FIRST TWO PATIENTS TREATED WITH INVESTIGATIONAL CRISPR/CAS9 GENE-EDITING THERAPY CTX001 FOR SEVERE HEMOGLOBINOPATHIES

Vertex deal with Wales expands cystic fibrosis treatment coverage to all of UK

Vertex Pharmaceuticals Inc's drugs for lung condition cystic fibrosis will now be available to patients across the UK after the company reached a pricing deal with Wales on Wednesday.

Vertex reaches deal with Wales for cystic fibrosis treatment

Vertex Pharmaceuticals Inc said on Wednesday cystic fibrosis patients in Wales would get access to the company's life-extending drugs following an agreement with the state-funded health service.

Vertex cystic fibrosis drug to be available in England after pricing deal

Cystic fibrosis patients in England will have access to life-extending drugs after the state-funded health service said it had agreed a pricing deal with manufacturer Vertex Pharmaceuticals.

Cystic fibrosis drug to be available in England after pricing deal

Cystic fibrosis patients in England will have access to life-extending drugs after the state-funded health service said it had agreed a pricing deal with manufacturer Vertex Pharmaceuticals.

Vertex prices cystic fibrosis combo treatment at $311,000-per-year

Vertex Pharmaceuticals Inc has priced its three-drug combination for cystic fibrosis (CF) at $311,503 per year, after winning early U.S. approval on Monday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up